AVL-292 Chemical Properties

Density 

1.322±0.06 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

≥21.15 mg/mL in DMSO; insoluble in H2O; ≥4.9 mg/mL in EtOH with gentle warming and ultrasonic

form 

solid

pka

13.22±0.70(Predicted)

CAS DataBase Reference

1202757-89-8

AVL-292 Usage And Synthesis

Uses

Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase involved in signal transduction pathways regulating the proliferation, activation, and differentiation of B cells. AVL-292 is an orally available, selective, and irreversible inhibitor of BTK (IC50 = 0.5 nM in vitro in B cell lymphoma cell lines) that targets and covalently binds to BTK at cysteine-481, thereby preventing its activity. AVL-292 has been shown to inhibit osteoclast function and to reduce osteoclast-stimulated proliferation of multiple myeloma cells in animal models of rheumatoid arthritis and multiple sclerosis, both of which are diseases where B cells play an important role. In clinical trials, AVL-292 has demonstrated therapeutic significance in the treatment of both B cell-related cancers (e.g., non-Hodgkin’s lymphoma and B cell chronic lymphocytic leukemia) and autoimmune diseases (e.g., rheumatoid arthritis).[Cayman Chemical]

target

Btk

AVL-292(1202757-89-8)Related Product Information

• Dabrafenib
• CAL-101
• CO-1686
• Ibrutinib
• AZD-9291
• CNX-774